Literature DB >> 16552619

Hamartin and tuberin modulate gene transcription via beta-catenin.

Jaroslaw Jozwiak1, Pawel Wlodarski.   

Abstract

Tuberous sclerosis, neurological genetic disorder characterized by the formation of benign tumors or hamartomas in multiple organ systems, is recently getting much attention. Numerous papers describe still-not-fully-explained pathogenesis of the disease. Studies on tuberous sclerosis allowed identification of two tumor suppressor genes, TSC1 and TSC2, encoding proteins implicated in the disease: hamartin and tuberin, respectively. The importance of these proteins is confirmed by their ubiquitous character and by the fact that TSC1/TSC2 complex is involved in the regulation of the activity of mTOR, a master controller of protein translation. Thus, the meaning of hamartin and tuberin goes far beyond tuberous sclerosis. As far as the influence of the TSC1/TSC2 complex on protein translation is well described in numerous reviews, little attention is drawn to the recently discovered role of the TSC1/TSC2 complex in gene transcription via the WNT signaling pathway. The present paper focuses on recent developments documenting the role of hamartin and tuberin in the WNT pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552619     DOI: 10.1007/s11060-006-9134-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma.

Authors:  D A Reardon; J J Jenkins; J E Sublett; P C Burger; L K Kun
Journal:  Pediatr Neurosurg       Date:  2000-04       Impact factor: 1.162

2.  Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.

Authors:  Dimpy Koul; Ruijun Shen; Sherry Bergh; Yiling Lu; John F de Groot; Ta Jen Liu; Gordon B Mills; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2005-11       Impact factor: 6.261

3.  Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.

Authors:  Y Niida; A O Stemmer-Rachamimov; M Logrip; D Tapon; R Perez; D J Kwiatkowski; K Sims; M MacCollin; D N Louis; V Ramesh
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

4.  Protein kinase CKII regulates the interaction of beta-catenin with alpha-catenin and its protein stability.

Authors:  Stephan Bek; Rolf Kemler
Journal:  J Cell Sci       Date:  2002-12-15       Impact factor: 5.285

5.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

6.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

7.  Aberrant beta-catenin signaling in tuberous sclerosis.

Authors:  Baldwin C Mak; Heidi L Kenerson; Lauri D Aicher; Elizabeth A Barnes; Raymond S Yeung
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

Review 8.  Medulloblastoma: developmental mechanisms out of control.

Authors:  Silvia Marino
Journal:  Trends Mol Med       Date:  2005-01       Impact factor: 11.951

9.  The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.

Authors:  Baldwin C Mak; Ken-Ichi Takemaru; Heidi L Kenerson; Randall T Moon; Raymond S Yeung
Journal:  J Biol Chem       Date:  2003-01-02       Impact factor: 5.157

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  7 in total

Review 1.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

Review 2.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

Review 3.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

4.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

5.  Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Jinling Hou; Kenneth Maiese
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 6.  Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

7.  Giant pilomatricoma in a patient with tuberous sclerosis, both diagnosed in the adult life.

Authors:  Cristina Isabel Pinho Resende; Joana Gomes; Maria da Luz Duarte; Celeste Brito
Journal:  BMJ Case Rep       Date:  2013-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.